REGENXBIO Inc. (NASDAQ:RGNX) Shares Sold by Vanguard Group Inc.

Vanguard Group Inc. cut its holdings in REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 31.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,985,952 shares of the biotechnology company's stock after selling 1,383,039 shares during the quarter. Vanguard Group Inc. owned approximately 6.03% of REGENXBIO worth $23,081,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Barclays PLC lifted its position in shares of REGENXBIO by 141.3% in the 3rd quarter. Barclays PLC now owns 116,024 shares of the biotechnology company's stock worth $1,217,000 after purchasing an additional 67,948 shares during the period. Assenagon Asset Management S.A. raised its stake in REGENXBIO by 53.0% in the fourth quarter. Assenagon Asset Management S.A. now owns 856,572 shares of the biotechnology company's stock worth $6,621,000 after buying an additional 296,700 shares in the last quarter. BNP Paribas Financial Markets lifted its holdings in REGENXBIO by 602.9% during the third quarter. BNP Paribas Financial Markets now owns 20,441 shares of the biotechnology company's stock worth $214,000 after buying an additional 17,533 shares during the period. FMR LLC boosted its position in REGENXBIO by 166.8% during the 3rd quarter. FMR LLC now owns 2,649 shares of the biotechnology company's stock valued at $28,000 after acquiring an additional 1,656 shares in the last quarter. Finally, Stifel Financial Corp increased its holdings in shares of REGENXBIO by 13.3% in the 3rd quarter. Stifel Financial Corp now owns 149,280 shares of the biotechnology company's stock valued at $1,566,000 after acquiring an additional 17,563 shares during the period. 88.08% of the stock is currently owned by institutional investors.

REGENXBIO Price Performance

RGNX traded down $0.22 on Friday, reaching $5.94. 649,002 shares of the stock were exchanged, compared to its average volume of 802,506. The company's 50-day moving average price is $6.81 and its 200 day moving average price is $8.13. The firm has a market capitalization of $297.69 million, a PE ratio of -1.18 and a beta of 1.26. REGENXBIO Inc. has a fifty-two week low of $5.04 and a fifty-two week high of $17.52.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last issued its quarterly earnings results on Thursday, March 13th. The biotechnology company reported ($1.01) earnings per share for the quarter, topping the consensus estimate of ($1.27) by $0.26. REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%. The company had revenue of $21.21 million for the quarter, compared to the consensus estimate of $23.70 million. As a group, equities analysts forecast that REGENXBIO Inc. will post -4.84 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on RGNX shares. Raymond James initiated coverage on REGENXBIO in a research note on Friday, February 7th. They set an "outperform" rating and a $27.00 price objective for the company. StockNews.com raised shares of REGENXBIO from a "sell" rating to a "hold" rating in a research report on Friday, March 7th. Leerink Partners set a $24.00 price objective on shares of REGENXBIO in a research report on Tuesday, March 18th. HC Wainwright decreased their target price on shares of REGENXBIO from $36.00 to $34.00 and set a "buy" rating for the company in a research report on Monday, March 17th. Finally, The Goldman Sachs Group cut their price target on shares of REGENXBIO from $14.00 to $12.00 and set a "neutral" rating on the stock in a report on Thursday. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat, REGENXBIO currently has an average rating of "Moderate Buy" and a consensus price target of $31.63.

REGENXBIO Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.